

ANTEGENES

Personalized genetics-based precision prevention of common complex diseases

We are looking for

- Distributors for our tests (medical companies, laboratories, healthcare providers)
- Public or private healthcare organizations for population-based healthcare programs (governmental organizations, health funds)
- Cooperation with genome programs and biobanks

Target markets

Global

Want to know more?

Founder & CEO Dr Peeter Padrik
peeter.padrik@antegenes.com
antegenes.com

OVERVIEW

Antegenes is an international pioneer of **precision preventive medicine**, aiming to use personal genetic information to reduce the severity and mortality due to common complex diseases (cancers, cardiovascular disease, diabetes, etc). As our individual disease risks are very different, prevention of cancer and other common complex diseases must be much more precise and efficient than currently.

Antegenes develops and implements advanced genetic tests based on polygenic risk scores technology to enable precision prevention. We inform individuals and their doctors about their genetic disease risks and provide actionable medical recommendations that reduce the likelihood, severity and mortality of common cancers and other complex diseases.

Antegenes has brought innovative CE-marked genetic tests relying on polygenic risk scores (in vitro medical devices, 98/79/EC) into clinical use:

- AnteBC – for breast cancer
- AntePC – for prostate cancer
- AnteCRC – for colorectal cancer
- AnteMEL – for melanoma

Based on our tests we have created and implemented genetics-based precision prevention programs.

Antegenes' products are created scientifically with laboratory and clinical validity and clinical usefulness, which makes them usable in healthcare by a broad range of healthcare professionals and institutions.



- Products are based on peer-reviewed international research and have been evaluated and validated using anonymized population data of the UK Biobank and Estonian Biobank.
- Tests are among the **first CE-marked** in vitro medical device (IVD) level polygenic risk score tests in the world.
- In development are tests for cardiovascular disease and diabetes, and adaptations for different ethnic backgrounds.

Antegenes® (est. 2018) is an ISO 13485 certified health-tech company and a registered healthcare service provider (laboratory services; medical genetics, oncology) in Estonia.



PARTNER